{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:01:04Z","timestamp":1758970864252},"reference-count":24,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Summary Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.<\/jats:p>","DOI":"10.1590\/1806-9282.63.03.203","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T18:03:41Z","timestamp":1493834621000},"page":"203-206","source":"Crossref","is-referenced-by-count":3,"title":["Diethylpropion and mazindol: An end to the discussion?"],"prefix":"10.1590","volume":"63","author":[{"given":"Rosa Camila","family":"Lucchetta","sequence":"first","affiliation":[{"name":"Universidade Federal do Paran\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Salgado","family":"Riveros","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosana Bento","family":"Radominski","sequence":"additional","affiliation":[{"name":"UFPR,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Fleith","family":"Otuki","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Ponta Grossa,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[{"name":"Universidade de Lisboa,  Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen B","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine society clinical practice guideline","volume":"100","author":"Apovian CM","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","article-title":"The efficacy and safety of sibutramine for weight loss: a systematic review","volume":"164","author":"Arterburn DE","year":"2004","journal-title":"Arch Intern Med"},{"key":"ref4","series-title":"Comunicados Oficiais","year":"2011"},{"key":"ref5","series-title":"Decreto legislativo n. 273, de 4 de setembro de 2014"},{"key":"ref6","series-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada - RDC n. 50, de 25 de setembro de 2014"},{"key":"ref7","series-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada - RDC n. 52, de 6 de outubro de 2011. Disp\u00f5e sobre a proibi\u00e7\u00e3o do uso das subst\u00e2ncias anfepramona, femproporex e mazindol, seus sais e is\u00f4meros, bem como intermedi\u00e1rios e medidas de controle da prescri\u00e7\u00e3o e dispensa\u00e7\u00e3o de medicamentos que contenham a subst\u00e2ncia sibutramina, seus sais e is\u00f4mer","year":"2011"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12328","article-title":"Update on obesity pharmacotherapy","volume":"1311","author":"Bray GA","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.publhealth.031308.100134","article-title":"Evidence-based public health: a fundamental concept for public health practice","volume":"30","author":"Brownson RC","year":"2009","journal-title":"Annu Rev Public Health"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1590\/S0102-311X2008000800005","article-title":"Prescription, dispensing, and regulation of psychoactive anorexigenic drugs in Belo Horizonte, Minas Gerais, Brazil","volume":"24","author":"Carneiro M de F","year":"2008","journal-title":"Cad Saude Publica"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/dom.12198","article-title":"The effect of antiobesity drugs on waist circumference: a mixed treatment comparison","volume":"16","author":"Chilton M","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias S","year":"2013","journal-title":"Med Decis Making"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.38","article-title":"Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA","volume":"2","author":"Eriksson R","year":"2014","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1467-789X.2009.00567.x","article-title":"Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis","volume":"10","author":"Fabricatore AN","year":"2009","journal-title":"Obes Rev"},{"issue":"25","key":"ref15","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen MD","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4239\/wjd.v2.i2.19","article-title":"Rise and fall of anti-obesity drugs","volume":"2","author":"Li M-F","year":"2011","journal-title":"World J Diabetes"},{"key":"ref17","article-title":"Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients","author":"Lucchetta R","year":"2017","journal-title":"Clinics"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0104-4230(11)70113-0","article-title":"Use of anti-obesity drugs among college students","volume":"57","author":"Martins MC","year":"2011","journal-title":"Rev Assoc Med Bras"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0104-4230(12)70160-4","article-title":"Evidence for the use of appetite suppressant drugs in Brazil: a pharmacoeconometric study","volume":"58","author":"Mota DM","year":"2012","journal-title":"Rev Assoc Med Bras"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1471-0153(01)00054-X","article-title":"Use of anorectic amphetamine-like drugs by Brazilian women","volume":"3","author":"Nappo SA","year":"2002","journal-title":"Eat Behav"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdt512","article-title":"How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views","volume":"25","author":"Tafuri G","year":"2014","journal-title":"Ann Oncol"},{"key":"ref22","series-title":"Guidance for Industry Developing Products for Weight Management (Draft Guidance)","year":"2007"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I(2) can be biased in small meta-analyses","volume":"15","author":"von Hippel PT","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"ref24","series-title":"Overweight and obesity","year":"2014"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v63n3\/0104-4230-ramb-63-03-0203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T04:28:36Z","timestamp":1495600116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302017000300203&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0104-42302017000300203"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.63.03.203","relation":{},"ISSN":["0104-4230"],"issn-type":[{"value":"0104-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}